Search

Search Constraints

You searched for: Issue Volume 110(2015)Supplement

Search Results

2472. Vedolizumab for Moderate to Severely Active Inflammatory Bowel Disease: A Multicenter U.S. Consortium: 1904. (October 2015)

2479. Virologic Response Rates to Fixed‐Dose Combination Ledipasvir/Sofosbuvir for 8 or 12 Weeks With Baseline Viral Load: 2061. (October 2015)